Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
Organogenesis Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.95|
|52 Week High||US$3.45|
|52 Week Low||US$24.34|
|1 Month Change||-29.31%|
|3 Month Change||-24.22%|
|1 Year Change||130.04%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-18.53%|
Recent News & Updates
Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of Organogenesis Holdings Inc. ( NASDAQ:ORGO ) by...
|ORGO||US Biotechs||US Market|
Return vs Industry: ORGO exceeded the US Biotechs industry which returned 12.4% over the past year.
Return vs Market: ORGO exceeded the US Market which returned 27.6% over the past year.
Stable Share Price: ORGO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ORGO's weekly volatility (9%) has been stable over the past year.
About the Company
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications.
Organogenesis Holdings Fundamentals Summary
|ORGO fundamental statistics|
Is ORGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ORGO income statement (TTM)|
|Cost of Revenue||US$103.92m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 09, 2021
|Earnings per share (EPS)||0.54|
|Net Profit Margin||16.17%|
How did ORGO perform over the long term?See historical performance and comparison
Is Organogenesis Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ORGO ($10.95) is trading below our estimate of fair value ($13.86)
Significantly Below Fair Value: ORGO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ORGO is good value based on its PE Ratio (20.1x) compared to the US Biotechs industry average (23.6x).
PE vs Market: ORGO is poor value based on its PE Ratio (20.1x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: ORGO is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: ORGO is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (2.9x).
How is Organogenesis Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORGO's forecast earnings growth (17.9% per year) is above the savings rate (2%).
Earnings vs Market: ORGO's earnings (17.9% per year) are forecast to grow faster than the US market (15.1% per year).
High Growth Earnings: ORGO's earnings are forecast to grow, but not significantly.
Revenue vs Market: ORGO's revenue (9.7% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: ORGO's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ORGO's Return on Equity is forecast to be low in 3 years time (17.8%).
How has Organogenesis Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORGO has a high level of non-cash earnings.
Growing Profit Margin: ORGO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ORGO has become profitable over the past 5 years, growing earnings by 41.2% per year.
Accelerating Growth: ORGO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ORGO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ORGO's Return on Equity (39.2%) is considered high.
How is Organogenesis Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: ORGO's short term assets ($201.8M) exceed its short term liabilities ($84.5M).
Long Term Liabilities: ORGO's short term assets ($201.8M) exceed its long term liabilities ($92.1M).
Debt to Equity History and Analysis
Debt Level: ORGO's debt to equity ratio (39%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ORGO's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ORGO's debt is well covered by operating cash flow (71.1%).
Interest Coverage: ORGO's interest payments on its debt are well covered by EBIT (7.5x coverage).
What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORGO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ORGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gary Gillheeney (66 yo)
Mr. Gary S. Gillheeney, Sr. serves as the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organog...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD2.48M) is below average for companies of similar size in the US market ($USD3.56M).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
Experienced Management: ORGO's management team is considered experienced (4.4 years average tenure).
Experienced Board: ORGO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ORGO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22%.
Organogenesis Holdings Inc.'s employee growth, exchange listings and data sources
- Name: Organogenesis Holdings Inc.
- Ticker: ORGO
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.434b
- Shares outstanding: 128.58m
- Website: https://organogenesis.com
Number of Employees
- Organogenesis Holdings Inc.
- 85 Dan Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 23:19|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.